QuantRx Biomedical Corporation
QTXB · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.99 | 0.02 | -0.03 | 0.00 |
| FCF Yield | -6.29% | -15.87% | -65.83% | -142.50% |
| EV / EBITDA | -78.78 | -78.77 | -11.72 | -8.29 |
| Quality | ||||
| ROIC | 1,862.93% | -287.89% | -354.09% | -47.17% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.19 | 0.30 | 0.31 | 0.35 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 33.96% | 60.91% | 25.69% | -71.25% |
| Safety | ||||
| Net Debt / EBITDA | -60.64 | -65.66 | -10.28 | -7.49 |
| Interest Coverage | -0.20 | -0.28 | -1.02 | -1.02 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |